Oz Medicann Group (OMG) has entered into an agreement aimed at speeding up the development and commercialisation of cannabinoid medicines throughout Asia.
Under the deal, South Korea-based biotech NeoCannBio (NCB) will receive exclusive rights to distribute products that emerge from clinical trial data generated by OMG.
The Australian company said trial data will support "parallel clinical programs and regulatory pathways across Asia, enabling more efficient market authorisation and faster access to evidence-based therapies".
China and India are excluded from the targeted regional markets.
OMG founder John Leith said the collaboration "reflects growing international confidence in Australian clinical research, regulatory standards, and innovation".
"By combining Australian science with strong regional partners, we are creating a responsible and scalable pathway to address real patient needs globally, while ensuring that intellectual property and clinical leadership remain Australian," he said.
Group chief executive Rohit Bhuta said OMG has multiple clinical trials underway, including projects to support potential schedule 3, over-the-counter regulatory pathways.
"This partnership enables NeoCannBio to leverage Australian clinical evidence to expedite registration discussions with regulators across Asia, potentially simplifying the pathway for patients to access clinically validated products without prescription," he said.
Bhuta said OMG is exploring comparable arrangements in other parts of the world as the company works to build a "scalable, international pathway anchored in Australian science".
NeoCannBio president Jeong Kook Kim described the move as a "long-term strategic alignment that combines Australian clinical excellence with our regional development and commercial capabilities".
"Together, we aim to deliver meaningful healthcare solutions across Asia while maintaining the highest standards of science, governance, and regulatory compliance," he said.
OMG is currently progressing a range of clinical trials covering sleep disorders, endometriosis, arthritis, and skin fungal infections.
